aTyr Pharma, Inc. Common Stock (ATYR) is a publicly traded Healthcare sector company. As of May 21, 2026, ATYR trades at $0.54 with a market cap of $50.94M and a P/E ratio of -0.67. ATYR moved +10.04% today. Year to date, ATYR is -28.87%; over the trailing twelve months it is -84.80%. Its 52-week range spans $0.40 to $7.29. Analyst consensus is neutral with an average price target of $7.33. Rallies surfaces ATYR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Atyr Pharma reports $10.8M Q1 loss, eyes June Phase 3 IND: Atyr Pharma reported a $10.8 million Q1 loss (11 cents per share) and held $68.3 million in cash and investments as of March 31. The company plans to file a June IND for a global Phase 3 pulmonary sarcoidosis trial using forced vital capacity as its primary endpoint.
| Metric | Value |
|---|---|
| Price | $0.54 |
| Market Cap | $50.94M |
| P/E Ratio | -0.67 |
| EPS | $-0.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.29 |
| 52-Week Low | $0.40 |
| Volume | 10.84K |
| Avg Volume | 0 |
| Revenue (TTM) | $190.00K |
| Net Income | $-74.12M |
| Gross Margin | 0.00% |
5 analysts cover ATYR: 0 strong buy, 1 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $7.33.